FOXO’s technology platform focussing on commercialising longevity science through product and service that serve the life insurance industry.
FOXO’s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company is on a mission to modernise the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance’s consumer value proposition with its FOXO Longevity Report.
Haven Life said it is “re-thinking how people financially protect the ones they love”. The insurer said it is committed to delivering exceptional products, “delightful purchasing experiences”, and meaningful moments of service to the modern life insurance customer.
FOXO LIFE, the insurance distribution subsidiary of FOXO Technologies, signed a managing general agency agreement with Haven Life.
Jim Grauel, Jr. chief distribution officer of FOXO LIFE, said, “This agreement will allow FOXO LIFE to rapidly expand its footprint among independent agent distribution channels. We have distribution partners excited to begin contracting and selling the innovative products offered through Haven Life.”
Wade Seward, head of partnership distribution at Haven Life, added, “The relationship between FOXO LIFE and Haven Life is a perfect fit as we grow within independent agent distribution channels. FOXO LIFE’s emphasis on improving the consumer aging experience and enhancing healthy longevity is everything we were looking for in a partner.”
Earlier this year, FOXO completed its special purpose acquisition (SPAC) with Delwinds.
FOXO first entered into a definitive merger agreement with SPAC company Delwinds Insurance Acquisition Corp in February this year.
The transaction was approved by Delwinds’ stockholders at its special meeting held on September 14, 2022. Over 91% of the votes cast on the business combination proposal at the special meeting were cast in favour of approving the business combination.
Copyright © 2022 FinTech Global